ICH Q11 Development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

  • Email
  • Help
Current effective version

Adopted guideline

 

Reference numberCHMP/ICH/425213/2011
Published01/05/2012
Effective from01/11/2012
KeywordsDrug substance, synthetic, biological, development, manufacture, dossier requirements, starting materials
DescriptionThis document describes approaches to developing and understanding the manufacturing process of the drug substance. It also provides guidance on what information should be provided in sections 3.2.S.2.2 – 3.2.S.2.6 (ICH M4Q). In addition, it provides further clarification on the principles and concepts described in ICH guidelines on pharmaceutical development (Q8), quality risk management (Q9) and pharmaceutical quality system (Q10).


Document history

First version

Current version

Adopted guideline


Draft guideline

In operation: 01/11/2011-present


Published: 01/05/2011

Questions and answers

(This Q&A document is intended to provide additional clarification relating to the selection and justification of starting materials)

 

Adopted questions and answers

 

Overview of comments

 

Draft questions and answers

Published: 06/10/2017

 

Published: 23/03/2017

 

 

Published: 15/12/2016


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more